De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
SpringWorks Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO SpringWorks Therapeutics' is Saqib Islam, benoemd in Jul2018, heeft een ambtstermijn van 6.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 18.35M, bestaande uit 4% salaris en 96% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.93% van de aandelen van het bedrijf, ter waarde $ 22.21M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.4 jaar en 5.2 jaar.
Belangrijke informatie
Saqib Islam
Algemeen directeur
US$18.4m
Totale compensatie
| Percentage CEO-salaris | 4.0% |
| Dienstverband CEO | 6.3yrs |
| Eigendom CEO | 0.9% |
| Management gemiddelde ambtstermijn | 4.4yrs |
| Gemiddelde ambtstermijn bestuur | 5.2yrs |
Recente managementupdates
Recent updates
SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
Aug 07Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
May 11
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15SpringWorks shows durable effect for neurofibroma therapy with long-term data
Jun 15SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma
Jun 07We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow
May 31SpringWorks Therapeutics EPS misses by $0.11
May 06Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$301m |
| Mar 31 2024 | n/a | n/a | -US$339m |
| Dec 31 2023 | US$18m | US$725k | -US$325m |
| Sep 30 2023 | n/a | n/a | -US$305m |
| Jun 30 2023 | n/a | n/a | -US$298m |
| Mar 31 2023 | n/a | n/a | -US$289m |
| Dec 31 2022 | US$15m | US$680k | -US$277m |
| Sep 30 2022 | n/a | n/a | -US$259m |
| Jun 30 2022 | n/a | n/a | -US$228m |
| Mar 31 2022 | n/a | n/a | -US$206m |
| Dec 31 2021 | US$18m | US$590k | -US$174m |
| Sep 30 2021 | n/a | n/a | -US$107m |
| Jun 30 2021 | n/a | n/a | -US$87m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$8m | US$541k | -US$46m |
| Sep 30 2020 | n/a | n/a | -US$73m |
| Jun 30 2020 | n/a | n/a | -US$68m |
| Mar 31 2020 | n/a | n/a | -US$62m |
| Dec 31 2019 | US$3m | US$480k | -US$51m |
| Sep 30 2019 | n/a | n/a | -US$41m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$18m |
| Dec 31 2018 | US$2m | US$407k | -US$18m |
Compensatie versus markt: De totale vergoeding ($USD 18.35M ) Saqib } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).
Compensatie versus inkomsten: De vergoeding van Saqib is gestegen terwijl het bedrijf verliesgevend is.
CEO
Saqib Islam (54 yo)
6.3yrs
Tenure
US$18,351,489
Compensatie
Mr. Saqib Islam, J.D. has been Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isla...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 6.3yrs | US$18.35m | 0.93% $ 22.3m | |
| Chief Financial Officer | 5.2yrs | US$3.74m | 0.025% $ 602.0k | |
| Chief Operating Officer | 3.8yrs | US$6.64m | 0.21% $ 5.0m | |
| Chief Medical Officer | 3.3yrs | US$4.31m | 0.031% $ 743.6k | |
| Chief Accounting Officer | 4.6yrs | geen gegevens | 0.0083% $ 198.5k | |
| Chief Scientific Officer | 1.1yrs | geen gegevens | geen gegevens | |
| Vice President of Communications & Investor Relations | 6.8yrs | geen gegevens | geen gegevens | |
| General Counsel & Secretary | 4.8yrs | US$2.83m | 0.018% $ 439.1k | |
| Chief People Officer | 4.2yrs | US$2.52m | 0.0065% $ 156.0k | |
| Chief Commercial Officer | 3.6yrs | US$4.94m | 0.014% $ 330.6k |
4.4yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SWTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 6.3yrs | US$18.35m | 0.93% $ 22.3m | |
| Independent Director | 5.2yrs | US$520.14k | 0.014% $ 340.6k | |
| Independent Chairman of the Board | 8.8yrs | US$545.14k | 0.41% $ 9.7m | |
| Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 7.2yrs | US$508.45k | 0.014% $ 340.6k | |
| Independent Director | 2.3yrs | US$507.64k | 0.011% $ 257.8k | |
| Independent Director | 4.4yrs | US$520.14k | 0% $ 0 |
5.2yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SWTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).